心力衰竭中的非编码RNA:表观遗传调节机制和治疗潜力
Yubo Ren1, Bomeng Zhao1, Luo Lv2
1Second College of Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, China.
Frontiers in genetics
|November 24, 2025
概括
非编码RNAs (ncRNAs) 通过改变表观遗传修饰,在心力衰竭中发挥关键作用. 针对ncRNA-表观遗传轴为心力衰竭治疗提供了新的精准医学策略.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 尽管有治疗方面的进步,但心力衰竭仍然是全球健康的重大负担.
- 新兴研究强调了非编码RNAs (ncRNAs) 在表观遗传调节驱动心脏重塑中的关键作用.
研究的目的:
- 将当前的证据综合到一个综合模型中,将ncRNAs,表观遗传学和心肌病联系起来.
- 探索ncRNAs作为心力衰竭中的生物标志物和治疗点的潜力.
主要方法:
- 关于ncRNAs,表观遗传学和心力衰竭的当前文献的综述.
- 将发现整合到"ncRNAs-epigenetics-cardiomyopathy"工作模型中.
- 对针对ncRNA-表观遗传轴的新兴治疗策略的评估.
主要成果:
- ncRNAs (microRNAs,长ncRNAs,圆形RNAs) 通过表观遗传修饰 (DNA甲基化,基因组,RNA修饰) 调节转录网络.
- 不同的ncRNA签名与心力衰竭表型,并发症和并发症有关,表明生物标志物的潜力.
- 新的治疗方法,包括反感性寡核酸和表观基因组编辑,显示出有希望的结果.
结论:
- ncRNA-表观遗传学轴是心力衰竭的病变发生的核心.
- 针对这一轴,为开发心力衰竭的精准医学策略提供了一个有希望的途径.
- 尽管存在翻译方面的挑战,但基于ncRNA的疗法对未来的心力衰竭管理具有重大潜力.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
895
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
895
01:29Heart Failure II: Pathophysiology
693
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
693
01:30Heart Failure V: Medical Management
204
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
204
01:17Pathophysiology of Heart Failure
2.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.7K
01:22Heart Failure Drugs: Diuretics
775
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
775
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K